Recent Updates
Recently added Catalysts
KPTI Positive Sentiment Score: 70/100

Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

Thursday, February 5, 2026 2 min read
Key Takeaway: Karyopharm Therapeutics Inc. has announced that it will report its fourth quarter and full year 2025 financial results on February 12, 2026. The management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss these results and provide other company updates. Karyopharm is recognized for its innovative cancer therapies and has a strong pipeline targeting various cancers.

Market Sentiment Analysis

POSITIVE FACTORS

  • Karyopharm is set to report financial results, indicating ongoing business activity.
  • The company is pioneering novel cancer therapies, showcasing innovation in the field.
  • Karyopharm's lead compound has received multiple regulatory approvals, reflecting its market potential.

Full Press Release Details

-- Conference Call Scheduled for Thursday, February 12, 2026, at 8:00 a.m. ET --
NEWTON, Mass.,Feb. 5, 2026/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 12, 2026, to discuss the financial results and other company updates.
To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeutics call. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website,http://investors.karyopharm.com/events-presentations. An archived webcast will be available on the Company's website approximately two hours after the event.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO®(selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in more than 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visitwww.karyopharm.com, and follow us onLinkedInand on X at @Karyopharm.
XPOVIO®and NEXPOVIO®are registered trademarks of Karyopharm Therapeutics Inc.
SOURCE Karyopharm Therapeutics Inc.

Frequently Asked Questions

When will Karyopharm report its financial results?

Karyopharm will report its fourth quarter and full year 2025 financial results on February 12, 2026.

What time is the Karyopharm conference call?

The conference call is scheduled for 8:00 a.m. ET on February 12, 2026.

How can I access the Karyopharm conference call?

To access the call, dial (800) 836-8184 locally or (646) 357-8785 internationally.

What is Karyopharm known for?

Karyopharm is known for pioneering novel cancer therapies, including its lead compound XPOVIO.

Tags: KPTI Viatris Investor Conferences Healthcare Karyopharm financial results cancer therapies XPOVIO
Last updated: Feb 5, 2026